IL233215A0 - Compound 2-(pyridine-2-yl)-7,1-diaza-spiro[4.4]nonane-6-one as a modulator of voltage-gated sodium channels - Google Patents
Compound 2-(pyridine-2-yl)-7,1-diaza-spiro[4.4]nonane-6-one as a modulator of voltage-gated sodium channelsInfo
- Publication number
- IL233215A0 IL233215A0 IL233215A IL23321514A IL233215A0 IL 233215 A0 IL233215 A0 IL 233215A0 IL 233215 A IL233215 A IL 233215A IL 23321514 A IL23321514 A IL 23321514A IL 233215 A0 IL233215 A0 IL 233215A0
- Authority
- IL
- Israel
- Prior art keywords
- diaza
- nonane
- spiro
- pyridin
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161579613P | 2011-12-22 | 2011-12-22 | |
| GBGB1122113.2A GB201122113D0 (en) | 2011-12-22 | 2011-12-22 | Novel compounds |
| PCT/GB2012/053233 WO2013093496A1 (en) | 2011-12-22 | 2012-12-21 | 2 - (pyridin- 2yl) - 1, 7 -diaza-spiro [4.4] nonane- 6 -one compound as voltage-gated sodium channels modulator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL233215A0 true IL233215A0 (en) | 2014-08-31 |
Family
ID=45572877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL233215A IL233215A0 (en) | 2011-12-22 | 2014-06-18 | Compound 2-(pyridine-2-yl)-7,1-diaza-spiro[4.4]nonane-6-one as a modulator of voltage-gated sodium channels |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US9376436B2 (en:Method) |
| EP (2) | EP2794612B1 (en:Method) |
| JP (2) | JP2015502395A (en:Method) |
| KR (1) | KR20140113692A (en:Method) |
| CN (1) | CN104271581B (en:Method) |
| AU (1) | AU2012356386A1 (en:Method) |
| BR (1) | BR112014014940A2 (en:Method) |
| CA (1) | CA2858938C (en:Method) |
| EA (1) | EA026500B1 (en:Method) |
| ES (1) | ES2581327T3 (en:Method) |
| GB (1) | GB201122113D0 (en:Method) |
| HK (2) | HK1203492A1 (en:Method) |
| IL (1) | IL233215A0 (en:Method) |
| IN (1) | IN2014MN01469A (en:Method) |
| MX (1) | MX2014007637A (en:Method) |
| SG (1) | SG11201403356YA (en:Method) |
| WO (2) | WO2013093497A1 (en:Method) |
| ZA (1) | ZA201404269B (en:Method) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201122113D0 (en) * | 2011-12-22 | 2012-02-01 | Convergence Pharmaceuticals | Novel compounds |
| GB201209015D0 (en) * | 2012-05-22 | 2012-07-04 | Convergence Pharmaceuticals | Novel compounds |
| RU2650523C1 (ru) * | 2017-07-24 | 2018-04-16 | федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) | Производное пиридоксина для лечения эпилепсии |
| SG11202002707VA (en) * | 2017-10-10 | 2020-04-29 | Biogen Inc | Process for preparing spiro derivatives |
| AU2018367909B2 (en) | 2017-11-17 | 2022-03-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of eye disorders |
| CN113563258A (zh) * | 2021-07-29 | 2021-10-29 | 派普医药(江苏)有限公司 | 一种4-溴-2-(二氟甲基)-5-甲基吡啶的制备方法 |
| WO2023044364A1 (en) | 2021-09-15 | 2023-03-23 | Enko Chem, Inc. | Protoporphyrinogen oxidase inhibitors |
| US20230150972A1 (en) * | 2021-09-24 | 2023-05-18 | Xenon Pharmaceuticals Inc. | Pyridinyl derivatives as sodium channel activators |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
| US5466823A (en) | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
| US5633272A (en) | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
| CA2212836C (en) | 1995-02-13 | 2003-08-12 | G.D. Searle & Co. | Substituted isoxazoles for the treatment of inflammation |
| UA57002C2 (uk) | 1995-10-13 | 2003-06-16 | Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. | Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування |
| BR9708574A (pt) | 1996-04-12 | 1999-08-03 | Searle & Co | Derivados benzeno sulfonamida substituídos como pródrogas de inibidores cox-2 |
| RS49881B (sr) | 1996-07-18 | 2008-08-07 | Merck Frosst Canada Ltd., | Supstituisani piridini kao selektivni inhibitori ciklooksigenaze-2 |
| CO4960662A1 (es) | 1997-08-28 | 2000-09-25 | Novartis Ag | Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados |
| EP1369421B1 (en) | 1997-09-05 | 2004-11-03 | Glaxo Group Limited | Pharmaceutical compositions comprising 2,3-Diaryl-pyrazolo[1,5-B]pyridazine derivatives |
| US7223772B1 (en) | 1998-11-03 | 2007-05-29 | Smithkline Beecham Corporation | Pyrazolopyridine derivatives as selective cox-2 inhibitors |
| US6025683A (en) | 1998-12-23 | 2000-02-15 | Stryker Corporation | Motor control circuit for regulating a D.C. motor |
| JP2002538157A (ja) | 1999-02-27 | 2002-11-12 | グラクソ グループ リミテッド | ピラゾロピリジン |
| GB0003224D0 (en) | 2000-02-11 | 2000-04-05 | Glaxo Group Ltd | Chemical compounds |
| GB0021494D0 (en) | 2000-09-01 | 2000-10-18 | Glaxo Group Ltd | Chemical comkpounds |
| GB0323204D0 (en) | 2003-10-03 | 2003-11-05 | Novartis Ag | Organic compounds |
| SE0302811D0 (sv) * | 2003-10-23 | 2003-10-23 | Astrazeneca Ab | Novel compounds |
| US8143306B2 (en) | 2005-10-10 | 2012-03-27 | Convergence Pharmaceuticals Limited | Methods of treating bipolar disorders |
| TW200730494A (en) | 2005-10-10 | 2007-08-16 | Glaxo Group Ltd | Novel compounds |
| TW200728258A (en) | 2005-10-10 | 2007-08-01 | Glaxo Group Ltd | Novel compounds |
| JP5139307B2 (ja) | 2005-10-10 | 2013-02-06 | グラクソ グループ リミテッド | ナトリウムチャネルモジュレーターとしてのプロリンアミド誘導体 |
| GB0520578D0 (en) * | 2005-10-10 | 2005-11-16 | Glaxo Group Ltd | Novel compounds |
| US7505330B2 (en) * | 2006-08-31 | 2009-03-17 | Micron Technology, Inc. | Phase-change random access memory employing read before write for resistance stabilization |
| GB0701365D0 (en) | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
| BRPI0807972A2 (pt) | 2007-01-24 | 2014-06-10 | Glaxo Group Ltd | Composições farmacêuticas compreendendo 3,5-diamino-6-(2,3-diclofenil)-l,2,4-triazina ou r(-)-2,4-diamino-5-(2,3-diclorofenil)-6-fluorometilpirim idina e uma nk1 |
| GB0701366D0 (en) | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
| GB0706630D0 (en) | 2007-04-04 | 2007-05-16 | Glaxo Group Ltd | Novel compounds |
| JP5855000B2 (ja) | 2009-09-14 | 2016-02-09 | クオンベルゲンセ プハルマセウトイカルス リミテッド | α−カルボキサミド誘導体の製造方法 |
| WO2011047174A1 (en) * | 2009-10-14 | 2011-04-21 | Xenon Pharmaceuticals Inc. | Synthetic methods for spiro-oxindole compounds |
| GB201122113D0 (en) * | 2011-12-22 | 2012-02-01 | Convergence Pharmaceuticals | Novel compounds |
| GB201209015D0 (en) | 2012-05-22 | 2012-07-04 | Convergence Pharmaceuticals | Novel compounds |
-
2011
- 2011-12-22 GB GBGB1122113.2A patent/GB201122113D0/en not_active Ceased
-
2012
- 2012-12-21 JP JP2014548202A patent/JP2015502395A/ja active Pending
- 2012-12-21 WO PCT/GB2012/053234 patent/WO2013093497A1/en active Application Filing
- 2012-12-21 WO PCT/GB2012/053233 patent/WO2013093496A1/en active Application Filing
- 2012-12-21 AU AU2012356386A patent/AU2012356386A1/en not_active Abandoned
- 2012-12-21 JP JP2014548201A patent/JP2015502394A/ja active Pending
- 2012-12-21 HK HK15103930.0A patent/HK1203492A1/xx unknown
- 2012-12-21 KR KR1020147019965A patent/KR20140113692A/ko not_active Withdrawn
- 2012-12-21 HK HK15104075.3A patent/HK1203501A1/xx unknown
- 2012-12-21 SG SG11201403356YA patent/SG11201403356YA/en unknown
- 2012-12-21 CN CN201280070485.0A patent/CN104271581B/zh not_active Expired - Fee Related
- 2012-12-21 EP EP12810417.1A patent/EP2794612B1/en not_active Not-in-force
- 2012-12-21 US US14/365,372 patent/US9376436B2/en not_active Expired - Fee Related
- 2012-12-21 EP EP12810416.3A patent/EP2797922B1/en not_active Not-in-force
- 2012-12-21 CA CA2858938A patent/CA2858938C/en active Active
- 2012-12-21 EA EA201491251A patent/EA026500B1/ru unknown
- 2012-12-21 BR BR112014014940A patent/BR112014014940A2/pt not_active Application Discontinuation
- 2012-12-21 MX MX2014007637A patent/MX2014007637A/es unknown
- 2012-12-21 IN IN1469MUN2014 patent/IN2014MN01469A/en unknown
- 2012-12-21 ES ES12810416.3T patent/ES2581327T3/es active Active
- 2012-12-21 US US14/365,391 patent/US9303032B2/en not_active Expired - Fee Related
-
2014
- 2014-06-10 ZA ZA2014/04269A patent/ZA201404269B/en unknown
- 2014-06-18 IL IL233215A patent/IL233215A0/en unknown
-
2016
- 2016-02-25 US US15/053,445 patent/US20160185758A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2794612A1 (en) | 2014-10-29 |
| GB201122113D0 (en) | 2012-02-01 |
| CA2858938C (en) | 2020-03-10 |
| US20140350040A1 (en) | 2014-11-27 |
| KR20140113692A (ko) | 2014-09-24 |
| US20150225400A1 (en) | 2015-08-13 |
| EP2794612B1 (en) | 2016-04-06 |
| EP2797922A1 (en) | 2014-11-05 |
| US20160185758A1 (en) | 2016-06-30 |
| ZA201404269B (en) | 2016-06-29 |
| US9303032B2 (en) | 2016-04-05 |
| IN2014MN01469A (en:Method) | 2015-04-17 |
| WO2013093497A1 (en) | 2013-06-27 |
| JP2015502395A (ja) | 2015-01-22 |
| MX2014007637A (es) | 2014-09-26 |
| EP2797922B1 (en) | 2016-04-06 |
| ES2581327T3 (es) | 2016-09-05 |
| EA026500B1 (ru) | 2017-04-28 |
| HK1203492A1 (en) | 2015-10-30 |
| CA2858938A1 (en) | 2013-06-27 |
| CN104271581B (zh) | 2016-08-31 |
| AU2012356386A1 (en) | 2014-07-10 |
| JP2015502394A (ja) | 2015-01-22 |
| BR112014014940A2 (pt) | 2017-06-13 |
| WO2013093496A1 (en) | 2013-06-27 |
| SG11201403356YA (en) | 2014-07-30 |
| EA201491251A1 (ru) | 2014-11-28 |
| CN104271581A (zh) | 2015-01-07 |
| US9376436B2 (en) | 2016-06-28 |
| HK1203501A1 (en) | 2015-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL233215A0 (en) | Compound 2-(pyridine-2-yl)-7,1-diaza-spiro[4.4]nonane-6-one as a modulator of voltage-gated sodium channels | |
| PT3686194T (pt) | Compostos de 2-(2,4,5-anilino-substituídos)pirimidina | |
| ZA201206440B (en) | [5,6]heterocyclic compound | |
| IL234485A (en) | Compounds based on imidazo [2,1 – b] pyridazine | |
| EP2875029B8 (en) | 5,5-heteroaromatic anti-infective compounds | |
| EP2699091A4 (en) | 2 ', 6'-dioxo-3'-deutero-PIPERIDIN-3-YL-isoindoline COMPOUNDS | |
| AP2010005408A0 (en) | Fused pyrimidineone compounds as TRPV3 modulators. | |
| EP2723741B8 (en) | Substituted imidazopyridinyl-aminopyridine compounds | |
| SI2384326T1 (sl) | Pirolo(2,3-d)pirimidinske spojine | |
| SI2694508T1 (sl) | Soli substituiranega 2,3-dihidroimidazo(1,2-C)kinazolina | |
| WO2012167171A3 (en) | Z-selective ring-closing metathesis reactions | |
| ZA201205788B (en) | 1,2,4-triazine-4-amine derivatives | |
| EP2624698A4 (en) | Furo [3,2-D] PYRIMIDINE COMPOUNDS | |
| AP2011005706A0 (en) | New compounds. | |
| IL232917A0 (en) | History of 5-(3-aminophenyl)-5-alkyl-6,5-dihydro-2h[4,1]oxazin-3-amine | |
| ZA201404074B (en) | 6-difluoromethyl-5,6-dihydro-2h-[1,4]oxazin-3-amine derivatives | |
| PL2531505T3 (pl) | Sposób wytwarzania kompleksów 3,7-diaza-bicyklo[3.3.1]nonanu z metalami | |
| ZA201306229B (en) | Substituted 4-aryl-n-phenyl-1,3,5-triazin-2- amines | |
| EP2687520A4 (en) | PROCESS FOR PREPARING A 1,2-BENZISOTHIAZOL-3-ON COMPOUND | |
| EP2883870B8 (en) | Method for producing 1,4-benzoxazine compound | |
| EP2687519A4 (en) | PROCESS FOR PRODUCING 1,2-BENZISOTHIAZOL-3-ONE COMPOUNDS | |
| SI2266990T1 (sl) | Spojina 3-fenilpirazolo(5,1-b)tiazola | |
| IL213762A0 (en) | 1,1,1-trifluoro-2-hydroxypropyl compounds | |
| IL228270A0 (en) | History of 1-h- pyrrolidine -4,2-dione spirocyclics converted in cis-alkoxy | |
| HK40086830A (en) | 2-(2,4,5-substituted-anilino)pyrimidine compounds |